Trending Now
ASCO 2019
Phase I Data for SAR408701 Supports Further Development in Lung Cancer
During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present a renewed strategy to address...
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
PEER REVIEW
EDITORIAL
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics. While the concept of ADCs is not...
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s...
In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose...
